Press release

Pierre Fabre unveils its ALL project: the largest international dermatology database.

20 June 2023

The project ALL: Over 50,000 people surveyed, in 20 countries, on 5 continents.

Castres, Tuesday, June 20, 2023 - On the occasion of the 25th World Congress of Dermatology (WCD), which will be held in Singapore from July 4 to 7, the Pierre Fabre Patient Relations Department will present the ALL project, a large-scale survey, the largest ever conducted in dermatology.

This project, launched at the end of 2022, with the help of the company EMMA, aims to collect data on all skin types (ALL Skins), all skin diseases (ALL Dermatoses) and all phototypes (ALL Colors) in order to build the largest international private database.

50,552 people, from the adult populations of 20 countries (representing more than 50% of the world’s population) on five continents, answered the 65 ALL project questions. 

The main themes discussed are related to the prevalence and the impact of medical conditions, but also the behaviors, care pathways and needs of patients affected by one or more dermatoses such as atopic dermatitis, psoriasis, acne, rosacea, and vitiligo (see complete list of subjects in Appendix 1).

The strength of this study lies in the considerable extent of the data collected and its representativeness: the respondents are drawn from samples proportional to the population of each country (sizes of samples per country in Appendix 2), enabling a very reliable analysis of needs on a global scale, by geographical territory. 

The ALL database has been built with analysis of results over time (longitudinal analysis), for 5 years (2023-2027). The 3.3 million data items thus compiled will identify the information essential to a better understanding of patient experiences.

“The creation of this incredible database confirms the commitment of the Pierre Fabre Group, which has been working alongside patients for many years to help improve their daily lives. Better understanding their expectations will allow us to focus our way of working to better support them in their dermatology care pathway,”


Medical Affairs and Patient & Consumer Relations Vice President at Pierre Fabre.

More than one in three people suffer from a skin disease, and yet health and prevention policies do not consider dermatology a public health priority. The ALL project aims to provide a global overview of the prevalence of the main skin diseases and their consequences in order to generate awareness among all stakeholders. Patients with dermatological diseases must receive more support and it is essential to convince the public authorities to give greater importance to dermatoses in prevention programs

This project, which is one of a kind, has already won the support of opinion leaders of international renown:  Dr. Jean Hilaire Saurat of the University of Geneva (acne), Dr. Gil Yosipovitch of the University of Miami (pruritus), Dr. Henry Lim of the University of Detroit and Dr. Khaled Ezzedine, dermatologist at the Paris Public Assistance Hospital (for photoprotection), Dr. Julien Seneschal, dermatologist at the Bordeaux University Hospital (vitiligo), and Dr. Marie Aleth Richard, dermatologist at the Marseilles Public Assistance Hospital and former president of the French Society of Dermatology.

The ALL study data will also be shared with patient associations in order to help them make their case to the general public, health care professionals and the authorities. Seven patient associations have already contributed to this initiative in France and abroad.

“For health care professionals, the ALL project is unique. Based on its methodology, it will allow us to describe, for the first time, the perceived prevalence of pruritus throughout the world, regardless of patients’ ethnicity, gender, age or region!”

says Dr. Gil Yosipovitch
Director of the Miami Itch Center (Dr. Phillip Frost, Dept. of Dermatology, Miller School of Medicine, Miami, Florida, USA).

About Pierre Fabre

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private pharmaceutical group in France.  Its portfolio includes several medical franchises and international brands, including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale AvèneKloraneDucrayRené FurtererA-DermaDarrowGlytoneNaturactive, Elgydium, Inava and Arthrodont.

In 2022, Pierre Fabre posted 2.7 billion euros in revenues, 69% of which came from international sales in over 120 countries, and invested more thant €170M in R&D. Established in the Occitanie region since its creation, and manufacturing over 90% of its products in France, the Group employs some 9,600 people worldwide. &Nbsp;

86% of the Pierre Fabre Group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation since 1999, and secondarily by its employees via an employee stock ownership plan.

In 2022, Pierre Fabre’s sustainability policy has been assessed by the independent AFNOR Certification body at the “Exemplary” level of its CSR label (ISO 26 000 standard for sustainable development). , @PierreFabre


Appendix 1: list of subjects studied

Acne, psoriasis, rosacea, eczema, lentigo, skin cancers, vitiligo, hair and nail disorders, wounds/healing, pain and pruritus, cosmetic procedures, oral care disorders, sun protection.

Appendix 2: sample sizes by country

5,000 people in China; 5,000 people in the United States; 4,001 people in Brazil; 4,001 people in Italy; 4,000 people in France; 4,000 people in Germany; 4,000 people in Spain; 3,000 people in India; 2,500 people in Canada; 2,500 people in Mexico; 2,500 people in Poland; 2,500 people in South Korea; 2,000 people in Australia; 1,000 people in Denmark; 1,000 people in Israel; 1,000 people in Portugal; 1,000 people in South Africa; 750 people in the United Arab Emirates; 500 people in Kenya; 400 people in Senegal.


Anne Kerveillant

+33 (0)6 20 88 54 57

We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.